Leuprolide Acetate 11.25mg Injection

Leuprolide Acetate 11.25mg is a depot gonadotropin-releasing hormone agonist used for hormone-dependent conditions when leuprolide acetate is prescribed. Depending on patient group and formulation, it may be used for prostate cancer, endometriosis, uterine fibroids, central precocious puberty, or other specialist-directed hormone-suppression indications. Leuprolide first stimulates and then downregulates pituitary GnRH receptors, leading to reduced LH and FSH release and lower sex-hormone production over time. Depot strength usually reflects dosing interval, so 3.75mg, 11.25mg, and 22.5mg products should not be treated as interchangeable.
Leuprolide Acetate 11.25mg is given as a depot injection by trained healthcare professionals. Keep injections on schedule because missed doses can reduce hormone suppression. Follow disease-specific monitoring.
Leuprolide initially stimulates and then suppresses pituitary GnRH signaling, reducing LH and FSH and lowering downstream sex-hormone production.
Possible effects include hot flashes, sweating, fatigue, mood changes, headache, injection-site reaction, reduced libido, sexual dysfunction, vaginal dryness or bleeding changes, and bone-density loss with longer use. Serious concerns include symptom flare, depression, seizures, severe allergic reaction, heart or glucose effects, and pituitary apoplexy symptoms.
Review indication, depot interval, pregnancy status, breastfeeding, unexplained vaginal bleeding, osteoporosis, depression, seizures, diabetes, heart disease, QT risk, prostate cancer urinary/spinal symptoms, and other hormonal medicines.
Specialist-managed hormone-dependent conditions such as prostate cancer, endometriosis, uterine fibroids, or central precocious puberty depending on formulation and indication.
Provides sustained hormone suppression that can reduce hormone-driven disease activity or symptoms with planned monitoring.
Leuprolide Acetate 11.25mg is used for specialist-managed hormone-dependent conditions for leuprolide depot therapy treatment.
Leuprolide can briefly stimulate hormones before suppressing them, causing temporary symptom worsening in some patients.
No. Depot strength usually matches a dosing interval and indication, so changes must be prescribed.
Longer hormone suppression can reduce bone density, especially in people already at osteoporosis risk.
Sudden severe headache, vision changes, severe allergic reaction, spinal weakness, or inability to urinate need urgent care.
Leuprolide acetate depot, GnRH agonist therapy, Hormone suppression, Prostate cancer endocrine therapy, Endometriosis fibroid treatment, Hot flashes bone density, AR: Leuprolide acetate حقن, FR: Leuprolide acetate, PT: Leuprolide acetate injeção, ES: Leuprolide acetate inyección, RU: Leuprolide acetate инъекция, ID: Leuprolide acetate injeksi, VI: Leuprolide acetate thuốc tiêm, MS: Leuprolide acetate suntikan, TL: Leuprolide acetate iniksyon, ZH-SG: Leuprolide acetate 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Leuprolide Acetate 11.25mg Injection under Fertility Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Leuprolide Acetate 11.25mg Injection